What should we know about metabolic syndrome and lipodystrophy in AIDS?

Detalhes bibliográficos
Autor(a) principal: Signorini,Dario Jose Hart Pontes
Data de Publicação: 2012
Outros Autores: Monteiro,Michelle Carreira Miranda, Andrade,Marion de Fátima Castro de, Signorini,Dario Hart, Eyer-Silva,Walter de Araújo
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista da Associação Médica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100017
Resumo: OBJECTIVE: Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects. METHODS: A total of 819 patients followed at a large outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied on agreement between patient's self-report and physician's observation of altered body-fat deposits. The presence of three or more of the following characteristics identified MS: increased waist circumference, hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic regression analyses to study variables independently associated with MS. RESULTS: The prevalence of MS was 20.6% and that of lipodystrophy was 38.5%. 61 (36.1%) out of 169 patients with MS had also lipodystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer exposure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome. CONCLUSION: Both traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with metabolic syndrome in the present study population.
id AMB-1_0c693210013246d5e392d83910b7078d
oai_identifier_str oai:scielo:S0104-42302012000100017
network_acronym_str AMB-1
network_name_str Revista da Associação Médica Brasileira (Online)
repository_id_str
spelling What should we know about metabolic syndrome and lipodystrophy in AIDS?Metabolic syndrome Xantiretroviral therapy, highly activeHIV-associated lipodystrophy syndromeHIVrisk factorscross-sectional studiesOBJECTIVE: Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects. METHODS: A total of 819 patients followed at a large outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied on agreement between patient's self-report and physician's observation of altered body-fat deposits. The presence of three or more of the following characteristics identified MS: increased waist circumference, hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic regression analyses to study variables independently associated with MS. RESULTS: The prevalence of MS was 20.6% and that of lipodystrophy was 38.5%. 61 (36.1%) out of 169 patients with MS had also lipodystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer exposure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome. CONCLUSION: Both traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with metabolic syndrome in the present study population.Associação Médica Brasileira2012-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100017Revista da Associação Médica Brasileira v.58 n.1 2012reponame:Revista da Associação Médica Brasileira (Online)instname:Associação Médica Brasileira (AMB)instacron:AMB10.1590/S0104-42302012000100017info:eu-repo/semantics/openAccessSignorini,Dario Jose Hart PontesMonteiro,Michelle Carreira MirandaAndrade,Marion de Fátima Castro deSignorini,Dario HartEyer-Silva,Walter de Araújoeng2012-02-28T00:00:00Zoai:scielo:S0104-42302012000100017Revistahttps://ramb.amb.org.br/ultimas-edicoes/#https://old.scielo.br/oai/scielo-oai.php||ramb@amb.org.br1806-92820104-4230opendoar:2012-02-28T00:00Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)false
dc.title.none.fl_str_mv What should we know about metabolic syndrome and lipodystrophy in AIDS?
title What should we know about metabolic syndrome and lipodystrophy in AIDS?
spellingShingle What should we know about metabolic syndrome and lipodystrophy in AIDS?
Signorini,Dario Jose Hart Pontes
Metabolic syndrome X
antiretroviral therapy, highly active
HIV-associated lipodystrophy syndrome
HIV
risk factors
cross-sectional studies
title_short What should we know about metabolic syndrome and lipodystrophy in AIDS?
title_full What should we know about metabolic syndrome and lipodystrophy in AIDS?
title_fullStr What should we know about metabolic syndrome and lipodystrophy in AIDS?
title_full_unstemmed What should we know about metabolic syndrome and lipodystrophy in AIDS?
title_sort What should we know about metabolic syndrome and lipodystrophy in AIDS?
author Signorini,Dario Jose Hart Pontes
author_facet Signorini,Dario Jose Hart Pontes
Monteiro,Michelle Carreira Miranda
Andrade,Marion de Fátima Castro de
Signorini,Dario Hart
Eyer-Silva,Walter de Araújo
author_role author
author2 Monteiro,Michelle Carreira Miranda
Andrade,Marion de Fátima Castro de
Signorini,Dario Hart
Eyer-Silva,Walter de Araújo
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Signorini,Dario Jose Hart Pontes
Monteiro,Michelle Carreira Miranda
Andrade,Marion de Fátima Castro de
Signorini,Dario Hart
Eyer-Silva,Walter de Araújo
dc.subject.por.fl_str_mv Metabolic syndrome X
antiretroviral therapy, highly active
HIV-associated lipodystrophy syndrome
HIV
risk factors
cross-sectional studies
topic Metabolic syndrome X
antiretroviral therapy, highly active
HIV-associated lipodystrophy syndrome
HIV
risk factors
cross-sectional studies
description OBJECTIVE: Prevalence of chronic complications of HIV infection is increasing and early recognition and treatment of the components of metabolic syndrome (MS) are essential to prevent cardiovascular and metabolic complications. Considering this, we performed a cross-sectional study on the prevalence and risk-factors for MS among HIV-infected subjects. METHODS: A total of 819 patients followed at a large outpatient HIV unit were assessed by an interviewer-administered questionnaire that recorded several demographic, epidemiologic, clinical, laboratory, and social variables. Lipodystrophy diagnosis relied on agreement between patient's self-report and physician's observation of altered body-fat deposits. The presence of three or more of the following characteristics identified MS: increased waist circumference, hypertriglyceridemia, low HDL cholesterol level, hypertension, and hyperglycemia. We used logistic regression analyses to study variables independently associated with MS. RESULTS: The prevalence of MS was 20.6% and that of lipodystrophy was 38.5%. 61 (36.1%) out of 169 patients with MS had also lipodystrophy. Patients with metabolic syndrome were significantly more likely to be older (OR = 1.08), had higher CD4 counts (OR = 1.001), had an increased body mass index (OR = 1.27) and had longer exposure to antiretroviral therapy (OR = 1.01) than those without metabolic syndrome. CONCLUSION: Both traditional risk factors for cardiovascular disease and factors associated with HIV infection itself, such as an increased CD4 cell count and a longer exposure to antiretroviral therapy, seem to be associated with metabolic syndrome in the present study population.
publishDate 2012
dc.date.none.fl_str_mv 2012-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100017
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302012000100017
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0104-42302012000100017
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Médica Brasileira
publisher.none.fl_str_mv Associação Médica Brasileira
dc.source.none.fl_str_mv Revista da Associação Médica Brasileira v.58 n.1 2012
reponame:Revista da Associação Médica Brasileira (Online)
instname:Associação Médica Brasileira (AMB)
instacron:AMB
instname_str Associação Médica Brasileira (AMB)
instacron_str AMB
institution AMB
reponame_str Revista da Associação Médica Brasileira (Online)
collection Revista da Associação Médica Brasileira (Online)
repository.name.fl_str_mv Revista da Associação Médica Brasileira (Online) - Associação Médica Brasileira (AMB)
repository.mail.fl_str_mv ||ramb@amb.org.br
_version_ 1754212830242930688